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There is considerable debate about the fundamental mechanisms that underlie and restrict acquisition of
human immunodeficiency virus type 1 (HIV-1) infection. In light of recent studies demonstrating the ability of
C type lectins to facilitate infection with HIV-1, we explored the potential relationship between polymorphisms
in the DC-SIGN promoter and risk for acquisition of HIV-1 according to route of infection. Using samples
obtained from 1,611 European-American participants at risk for parenteral (n  713) or mucosal (n  898)
infection, we identified single-nucleotide polymorphisms in the DC-SIGN promoter using single-strand con-
formation polymorphism. Individuals at risk for parenterally acquired infection who had 336C were more
susceptible to infection than were persons with336T (odds ratio 1.87, P 0.001). This association was not
observed in those at risk for mucosally acquired infection. A potential role for DC-SIGN specific to systemic
acquisition and dissemination of infection is suggested.
Dendritic cells (DCs) play a critical role in initiating the
immune response by virtue of their ability to capture antigens
and present them to T cells (1). Although the precise mecha-
nisms of human immunodeficiency virus (HIV) acquisition are
not completely understood, migration of DCs from peripheral
tissues and blood to regions of draining lymphoid organs may
enable their capture of HIV type 1 (HIV-1) and presentation
of virus to CD4 T cells (16). HIV-1 entry into target cells is
mediated by interactions of the viral envelope glycoprotein
with CD4 and the chemokine receptors CCR5 and CXCR4 on
the target cell membrane, although entry may be influenced by
other factors as well. DC-SIGN (DC-specific intercellular ad-
hesion molecule 3 [ICAM-3] grabbing nonintegrin), encoded
by a member of the CD209 gene family on chromosome
19p13.2–3, has recently been identified as a DC-specific adhe-
sion receptor that mediates the interaction between DCs and
resting T cells through high-affinity binding to ICAM-3 (6).
DC-SIGN also binds HIV-1 gp120, facilitating capture of HIV
and enhancing in vitro infection of T cells in trans. DC-SIGN-
associated HIV-1 remains infectious over a prolonged period,
perhaps contributing to the infectious potential of the virus
during its transport by DCs from the periphery to lymphoid
organs (5). This receptor may represent a common thread in
many infectious diseases, as it has also been shown to facilitate
direct infection of DCs by a range of infectious agents, such as
Dengue virus, Ebola virus, human cytomegalovirus, Leishma-
nia pifanoi amastigotes, and Mycobacterium tuberculosis (re-
viewed in reference 17). Thus it is plausible that polymor-
phisms in the gene might have a broad range of influence in the
pathogenesis of human infectious disease in general, including
HIV-1.
Given the functional activity of DC-SIGN, we proposed that
polymorphisms in the coding region and/or promoter region of
the associated gene might influence outcomes after HIV-1
exposure. Initial screening for nucleotide variation indicated
conservation of DC-SIGN coding sequences. However, several
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TABLE 1. DC-SIGN promoter region haplotypes
Haplotypea f b
Nucleotide at position:
139 336 939 1089 1180 1466 1530
1 0.28 C T T C T C A
2 0.26 T T C C A T A
3 0.15 C T T C T T A
4 0.07 C C C C A C A
5 0.07 T T C A A T A
6 0.05 C C C C A C C
7 0.04 T T C C A C A
8 0.03 C C C C T C A
a Only haplotypes with a frequency of 1% are shown. Haplotypes were
estimated in compound heterozygotes with the expectation maximization algo-
rithm.
b f, frequency.
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FIG. 1. DC-SIGN promoter polymorphisms and susceptibility to parenterally and mucosally acquired infection. (A) Frequency of DC-SIGN
promoter polymorphisms in HIV-1-infected individuals (HIV-1 ) and HIV-seronegative individuals (HIV-1 ). P values and ORs are listed
below each SNP. (B) Frequency of 336C in HIV-1-infected individuals and HIV-negative individuals (HREU, high risk exposed uninfected; all
SN, all HIV-seronegative individuals) from all cohorts combined (all) and in individual cohorts (MHCS [Multicenter Hemophilia Cohort Study]
and ALIVE [AIDS Linked to Intravenous Experience]).
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single-nucleotide polymorphisms (SNPs) were identified in the
region 2 kb upstream of the ATG start codon, which includes
the promoter region (11). The region was amplified in four
overlapping segments of 200 to 300 bp, and analysis of the
products was performed using single-strand conformation poly-
morphism (SSCP), as previously described (3). All variants
identified by SSCP were confirmed by sequencing analysis. We
genotyped samples from 1,611 European-American (EA) par-
ticipants in five well-characterized HIV-1 cohorts at risk for
parenteral (Multicenter Hemophilia Cohort Study [7], AIDS
Linked to Intravenous Experience [18], and Hemophilia
Growth and Development Study [9]) or mucosal acquisition
(Multicenter AIDS Cohort Study [13] and San Francisco City
Clinic Cohort [2]) of HIV-1 infection for the DC-SIGN pro-
moter polymorphisms. Six common and 10 rare variants that
defined eight haplotypes with frequencies1% were identified
(Table 1). The frequency distributions of the most common
DC-SIGN promoter SNPs (139, 336, 939, 1180, and
1466) were compared among 544 uninfected EA participants
and 1,067 HIV-1-infected EA participants. The 139T SNP
(odds ratio [OR]  0.77, P  0.03) was slightly overrepre-
sented among HIV-1-uninfected participants, whereas the op-
posite was found for the 336C SNP (Fig. 1A). In addition,
244 uninfected and 520 infected African-Americans within these
cohorts were genotyped, but no significant differences in geno-
type frequencies were observed in this group (data not shown).
It has been suggested that DC-SIGN might not be involved
in sexual transmission of HIV because it is not expressed by
Langerhans cells, mucosal DCs in the genital tract (14). There-
fore, further analyses were performed, with participants strat-
ified according to route of infection. No significant difference
in risk was seen for any of the SNPs in the mucosal group
(Table 2). However, among all parenterally exposed partici-
pants there was a significant association with increased likeli-
hood of infection for those with the 336C SNP (OR  1.87,
P  0.001). This association remained statistically significant
after correction for multiple tests (P  0.005). The strength of
the association was increased when the analysis was restricted
to HIV-1-negative individuals at highest risk for infection
(those with documented receipt of HIV-1-contaminated clot-
ting factor; OR  2.46), though significance was diminished to
some extent (P  0.014), probably as a consequence of the
reduced numbers (50 high-risk individuals versus a total of 365
uninfected individuals) (Fig. 1B). Importantly, similar trends
were seen in individual cohorts (Fig. 1B).
Haplotype analysis revealed that haplotype 4, which contains
all of the high-risk SNPs, was also associated with parenterally
acquired infection (OR  2.62, P  0.018). Indeed, the effect
is somewhat stronger, although less significant, and signifi-
cance was lost after correction for multiple tests. None of the
other haplotypes showed a significant association with infec-
tion. The haplotype containing all protective SNPs (139T,
336T, 939T, 1180T, and 1466T) was quite rare (fre-
quency  0.001), so it was not possible to test the influence of
this haplotype on the risk of HIV-1 infection. There was no
significant association seen with HIV-1 disease progression for
any of the individual SNPs or haplotypes.
DCs are believed to play a central role in HIV-1 infection as
they may be among the first cells encountered by virus (5). DC-
SIGN, a C-type lectin receptor that is exclusively expressed by
DCs, can enhance virus infection by efficiently binding to the
envelope glycoprotein of both R5 and X4 viruses (5). Levels of
DC-SIGN expression on subsets of DCs are variable, however,
and Langerhans cells, a subset of DCs that are present in the
genital epithelium, do not express DC-SIGN at all (6). Fur-
thermore, infection of these cells is blocked by inhibitors of
CCR5 expression and not by C type lectin inhibitors (10).
Thus, it is plausible that CCR5-dependent infection of Lang-
erhans cells, and not DC-SIGN-mediated capture of HIV-1, is
the major pathway involved in sexual transmission of HIV-1
(14), accounting for the failure to demonstrate a significant
association of DC-SIGN polymorphism and mucosal infection.
On the other hand, DC-SIGN expressed in lymph nodes and
circulating DCs may play a role in HIV-1 acquisition via the
parenteral route. In this regard, heterogeneity in expression of
DC-SIGN among healthy subjects (4) may determine the abil-
ity of these cells to potentiate infection. Polymorphism in the
promoter region of CCR5 has been shown to have an effect on
HIV-1 disease progression (12), CCR5 surface density (15),
and susceptibility of cells to HIV-1 infection (10, 15). Here we
show that a polymorphism in the putative promoter region of
DC-SIGN is associated with risk of infection via the parenteral
route but not the mucosal route. A potential mechanism for
this may involve differential constitutive or inducible expres-
sion of DC-SIGN on blood DCs as a result of this polymor-
phism, but this remains to be demonstrated. 336C is located
214 bp upstream of the major transcription start site (11) and
is therefore likely to be in a region containing potential binding
sites for transcriptional factors. Indeed, a database search
(TRANSFAC database) (8) identified a potential Sp1 binding
site in the presence of 336C, which is lost when 336T is
present. Functional analyses should determine whether or not
this is biologically significant.
Although the 336C SNP was quite common in African-
Americans, there was no significant association with risk of
infection seen for this group. This raises the possibility that the
effect seen in Caucasians is not due directly to 336C, but
rather to another as yet unidentified SNP on chromosome
19p13.2–3 that is in linkage disequilibrium with336C in Cau-
casians but not in African Americans. Alternatively, 336C
may exert its protective effect only in the presence of another
variant that is common in Caucasians but missing in African-
Americans.
Further studies are necessary to demonstrate the role of
DC-SIGN promoter polymorphisms identified in this study in
the function of DC-SIGN, and consequently their effect on
TABLE 2. DC-SIGN promoter polymorphisms and susceptibility
to parenteral and mucosal infection
Variant
Parenteral infection Mucosal infection
Phenotypic
frequency
OR P
Phenotypic
frequency
OR P
HIV-1
(n  348)
HIV-1
(n  365)
HIV-1
(n  719)
HIV-1
(n  179)
139T 0.53 0.63 0.66 0.03 0.60 0.66 0.76 0.17
336C 0.44 0.29 1.87 0.001 0.36 0.39 0.87 0.46
939T 0.52 0.61 0.69 0.05 0.60 0.64 0.84 0.41
1180T 0.75 0.81 0.73 0.15 0.82 0.83 0.94 0.81
1466T 0.69 0.77 0.69 0.08 0.77 0.80 0.85 0.51
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HIV-1 infection. It will also be of interest to determine wheth-
er the 336C SNP is associated with protection from or sus-
ceptibility to other pathogens known to bind DC-SIGN.
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